U.S. purchases another 100K doses of Lilly COVID-19 antibodies

By The Science Advisory Board staff writers

February 26, 2021 -- The U.S. government is purchasing a minimum of 100,000 doses of Eli Lilly's bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1,400 mg together, which are neutralizing antibodies that can treat mild to moderate COVID-19 in patients who are at high risk of progressing to a severe stage.

The government will pay Lilly $210 million and doses will be delivered through March 31. The government also has the option to purchase up to an additional 1.1 million doses through November 25 under the same terms as the base agreement.

The purchase agreement is on top of the U.S. government's commitment to buy a total of 1.45 million doses of bamlanivimab alone -- 1 million of which have already been delivered and the remaining 450,000 doses to follow suit by the end of March.

The neutralizing antibodies will be provided at no out-of-pocket cost to patients, but healthcare facilities may charge a fee for the product's administration, Lilly said.

Eli Lilly gets EUA for COVID-19 mAb combo
The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to Eli Lilly for the combination of the monoclonal antibodies (mAbs)...
Top biopharma companies form data exchange nonprofit
Ten of the world's largest biopharmaceutical companies publicly launched a new nonprofit corporation, Accumulus Synergy. The aim is to support interactions...
Lilly's mAb highly protective against COVID-19 in nursing homes
Eli Lilly's monoclonal antibody (mAb) LY-CoV555 (bamlanivimab) significantly reduced the risk of contracting COVID-19 among residents and staff of long-term...
Lilly, Merus to develop T-cell redirecting bispecific antibodies
Eli Lilly research and development group Loxo Oncology and oncology firm Merus have signed a research collaboration and exclusive license agreement with...
Lilly to acquire Prevail Therapeutics for $1B
Eli Lilly will acquire Prevail Therapeutics for a total consideration of up to $26.50 per share in cash, or an aggregate of approximately $1.04 billion,...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter